Metronomic antiangiogenic chemotherapy: recent preclinical and clinical advances

被引：0
作者：
Kerbel, R. S. [1 ]
机构：
[1] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(06)70022-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
17
引用
收藏
页码：9 / 10
页数：2
相关论文
共 4 条
  • [1] Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients
    Bottini, Alberto
    Generali, Daniele
    Brizzi, Maria Pia
    Fox, Stephen B.
    Bersiga, Alessandro
    Bonardi, Simone
    Allevi, Giovanni
    Aguggini, Sergio
    Bodini, Giuliana
    Milani, Manuela
    Dionisio, Rossana
    Bernardi, Claudio
    Montruccoli, Arianna
    Bruzzi, Paolo
    Harris, Adrian L.
    Dogliotti, Luigi
    Berruti, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (22) : 3623 - 3628
  • [2] Antiangiogenic therapy: A universal chemosensitization strategy for cancer?
    Kerbel, Robert S.
    [J]. SCIENCE, 2006, 312 (5777) : 1171 - 1175
  • [3] The anti-angiogenic basis of metronomic chemotherapy
    Kerbel, RS
    Kamen, BA
    [J]. NATURE REVIEWS CANCER, 2004, 4 (06) : 423 - 436
  • [4] Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy
    Mancuso, Patrizia
    Colleoni, Marco
    Calleri, Angelica
    Orlando, Laura
    Maisonneuve, Patrick
    Pruneri, Giancarlo
    Agliano, Alice
    Goldhirsch, Aron
    Snaked, Yuval
    Kerbel, Robert S.
    Bertolini, Francesco
    [J]. BLOOD, 2006, 108 (02) : 452 - 459
1